In conclusion, cisplatin treatment under the influence of CM from fibroblasts and endothelial cells led to deregulation of genes involved in ‘post‐’ (TP53, BCL2, BCLXL) and ‘off‐target’ (ERBB2) resistance mechanisms in most analyzed GCT cell lines. The gene discussed is BCL2L1; the disease is granular cell tumor.